FDA clears Mobius glaucoma drug

Mitosol delivers a precise dose of its active ingredient, mitomycin-c, providing ophthalmic surgeons for use in procedures without any change to their current technique.

In collaboration with St Louis-based sterile packaging, precision medical molding, commercial sterilization and pharmaceutical logistic firms, Mobius manufactures Mitosol.

Mobius Therapeutics president Ed Timm said Mitosol will provide surgeons, hospitals, and patients with improved convenience, safety, and consistency in the surgical treatment of glaucoma.

"The approval of Mitosol for use in glaucoma surgery represents the culmination of more than five years of work on the part of Mobius Therapeutics," Timm added.

Mobius Therapeutics is an early stage venture focused on ophthalmic surgery solutions.